Larimar Therapeutics, Inc. (LRMR) intrinsic value & 10-year financials
Larimar Therapeutics, Inc. (LRMR) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.99
- Market cap
- $121.6M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -127.9%
- Free cash flow (FY2025)
- -$113.3M
LRMR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$165.7M | — | -$113.3M | — | -249.5% |
| FY2024 | — | -$80.6M | -$1.32 | -$71.3M | — | -89.8% |
| FY2023 | — | -$36.9M | -$0.84 | -$33.6M | — | -56.2% |
| FY2022 | — | -$35.4M | -$1.37 | -$27.7M | — | -82.5% |
| FY2021 | — | -$50.6M | -$2.95 | -$42.4M | — | -370.1% |
| FY2020 | — | -$42.5M | -$3.57 | -$42.3M | — | -114.2% |
| FY2019 | $0 | -$45.4M | — | -$41.5M | — | -82.0% |
| FY2018 | $0 | -$61.4M | — | -$51.6M | — | -100.7% |
| FY2017 | $0 | -$52.0M | — | -$43.8M | — | -70.7% |
| FY2016 | $0 | -$57.9M | — | -$52.6M | — | -62.9% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Larimar Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Larimar Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -66.5% ROIC.
Larimar Therapeutics, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Larimar Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.